Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 785705, 7 pages
http://dx.doi.org/10.1155/2015/785705
Research Article

Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome

1Department of Rheumatology and Internal Diseases, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-252 Szczecin, Poland
2Independent Laboratory of Rheumatic Diagnostics, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-252 Szczecin, Poland

Received 8 December 2014; Revised 15 March 2015; Accepted 22 March 2015

Academic Editor: György Nagy

Copyright © 2015 Hanna Przepiera-Będzak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Gratacós, A. Collado, X. Filella et al., “Serum cytokines (IL-6, TNF-alpha, IL-beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity,” British Journal of Rheumatology, vol. 33, no. 10, pp. 927–931, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Bal, E. Unlu, G. Bahar, E. Aydog, E. Eksioglu, and R. Yorgancioglu, “Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis,” Clinical Rheumatology, vol. 26, no. 2, pp. 211–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Hayer, B. Niederreiter, I. Nagelreiter, J. Smolen, and K. Redlich, “Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1403–1406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. K. Singh, R. Misra, and A. Aggarwal, “Th-17 associated cytokines in patients with reactive arthritis/undifferentiated spondyloarthropathy,” Clinical Rheumatology, vol. 30, no. 6, pp. 771–776, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Wendling, “Interleukin 23: a key cytokine in chronic inflammatory disease,” Joint Bone Spine, vol. 75, no. 5, pp. 517–519, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. H. Gaston, J. C. Goodall, and D. Baeten, “Interleukin-23: a central cytokine in the pathogenesis of spondylarthritis,” Arthritis and Rheumatism, vol. 63, no. 12, pp. 3668–3671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Cauli and A. Mathieu, “Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis,” Journal of Rheumatology, vol. 39, no. 89, pp. 15–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Wendling, J.-P. Cedoz, and E. Racadot, “Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients,” Clinical Rheumatology, vol. 28, no. 2, pp. 187–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Melis, B. Vandooren, E. Kruithof et al., “Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 3, pp. 618–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Goldberger, J. Dulak, C. Duftner, F. Weidinger, A. Falkenbach, and M. Schirmer, “Vascular endothelial growth factor (VEGF) in ankylosing spondylitis—a pilot study,” Wiener Medizinische Wochenschrift, vol. 152, no. 9-10, pp. 223–225, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Drouart, P. Saas, M. Billot et al., “High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies,” Clinical and Experimental Immunology, vol. 132, no. 1, pp. 158–162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Fink, E. Cauza, W. Hassfeld et al., “Vascular endothelial growth factor in patients with psoriatic arthritis,” Clinical and Experimental Rheumatology, vol. 25, no. 2, pp. 305–308, 2007. View at Google Scholar · View at Scopus
  13. C. Butt, S. Lim, C. Greenwood, and P. Rahman, “VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis,” BMC Musculoskeletal Disorders, vol. 8, article 1, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis & Rheumatism, vol. 27, no. 4, pp. 361–368, 1984. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, and H. Mielants, “Classification criteria for psoriatic arthritis: development of new criteria from a large international study,” Arthritis & Rheumatism, vol. 54, no. 8, pp. 2665–2673, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. F. Kahn and M. A. Khan, “The SAPHO—syndrome,” in Psoriatic Arthritis, V. Wright and P. Helliwell, Eds., vol. 8 of Baillière's Clinical Rheumatology, pp. 333–362, 1994. View at Google Scholar
  17. D. M. Ashcroft, A. Li Wan Po, H. C. Williams, and C. E. M. Griffiths, “Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality,” British Journal of Dermatology, vol. 141, no. 2, pp. 185–191, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin, “A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index,” Journal of Rheumatology, vol. 21, no. 12, pp. 2286–2291, 1994. View at Google Scholar · View at Scopus
  19. G.-M. Alenius, C. Eriksson, and S. R. Dahlqvist, “Interleukin-6 and soluble interleukin-2 receptor alpha—markers of inflammation in patients with psoriatic arthritis?” Clinical & Experimental Rheumatology, vol. 27, no. 1, pp. 120–123, 2009. View at Google Scholar · View at Scopus
  20. S. Visvanathan, C. Wagner, J. C. Marini et al., “Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab,” Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 511–517, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Londono, M. C. Romero-Sanchez, V. G. Torres et al., “The association between serum levels of potential biomarkers with the presence of factors related to the clinical activity and poor prognosis in spondyloarthritis,” Revista Brasileira de Reumatologia, vol. 52, no. 4, pp. 536–544, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Brulhart, M. J. Nissen, P. Chevallier, and C. Gabay, “Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists,” Joint Bone Spine, vol. 77, no. 6, pp. 625–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Shima, T. Tomita, T. Ishii et al., “Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis,” Modern Rheumatology, vol. 21, no. 4, pp. 436–439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-D. Cohen, R. Ferreira, and C. Jorgensen, “Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab,” Journal of Rheumatology, vol. 38, no. 7, p. 1527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Hughes and H. Chinoy, “Successful use of tocilizumab in a patient with psoriatic arthritis,” Rheumatology, vol. 52, no. 9, Article ID kes432, pp. 1728–1729, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Sieper, B. Porter-Brown, L. Thompson, O. Harari, and M. Dougados, “Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials,” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 95–100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Ogata, N. Umegaki, I. Katayama, A. Kumanogoh, and T. Tanaka, “Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab,” Joint Bone Spine, vol. 79, no. 1, pp. 85–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Duan, F. Pan, Z. Zeng et al., “Interleukin-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis,” Rheumatology International, vol. 32, no. 5, pp. 1209–1214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Rahman, R. D. Inman, W. P. Maksymowych, J. P. Reeve, L. Peddle, and D. D. Gladman, “Association of interleukin 23 receptor variants with psoriatic arthritis,” Journal of Rheumatology, vol. 36, no. 1, pp. 137–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Gottlieb, A. Menter, A. Mendelsohn et al., “Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial,” The Lancet, vol. 373, no. 9664, pp. 633–640, 2009. View at Publisher · View at Google Scholar
  31. I. B. McInnes, A. Kavanaugh, A. B. Gottlieb et al., “Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial,” The Lancet, vol. 382, no. 9894, pp. 780–789, 2013. View at Publisher · View at Google Scholar
  32. G. Safa, A. Martin, and L. Darrieux, “Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis,” Journal of Clinical Rheumatology, vol. 17, no. 7, pp. 385–386, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Appel, R. Maier, J. Bleil et al., “In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis,” Arthritis and Rheumatism, vol. 65, no. 6, pp. 1522–1529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Przepiera-Będzak, K. Fischer, and M. Brzosko, “Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome,” Polskie Archiwum Medycyny Wewnetrznej, vol. 123, no. 6, pp. 297–302, 2013. View at Google Scholar · View at Scopus